Results 91 to 100 of about 418,673 (161)

Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration

We described insulin glargine (originator) and insulin glargine-yfgn (biosimilar) treatment patterns, assessed effectiveness and safety outcomes, and identified reasons for switching back to the originator product from the biosimilar.
Diane Dong, Donald R. Miller, Anthony Au, Samantha Walczuk, Deborah Khachikian, Kelly Bryan, Cedric Salone, Xinhua Zhao, Sherrie L. Aspinall, Francesca E. Cunningham, Peter A. Glassman, Qoua Her   +11 more
core   +1 more source

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long-Acting Insulin Analogues for Diabetes Mellitus. [PDF]

Diabetes Obes Metab
Bolli GB, Home PD, Lepore M, Riddle MC, Porcellati F, Fanelli CG, Lucidi P, Yki-Järvinen H, Becker RH, Owens DR.   +9 more
europepmc   +1 more source

Clinical Outcomes of Insulin Glargine U300 on Glycemic Control and Hypoglycemia: A Retrospective Observational Study. [PDF]

J Clin Med
Güngör Semiz G, Ünal MÇ, Selimoğlu İ, Kalender S, Erbay E, Arayici ME, Çömlekçi A, Yener S, Demir T.   +8 more
europepmc   +1 more source

Beyond Glycemic Control: Real-World 12-Month Effects of Insulin Glargine/Lixisenatide on Weight, Endogenous Insulin Secretion, and Albuminuria. [PDF]

J Clin Med
Ozturk S, Akyol EMB.
europepmc   +1 more source

Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect Study. [PDF]

Diabetes Ther
Bellido V, Cebrián A, Morales C, de Las Hazas AS, Soto-Gonzalez A, Morer-Liñan C, Borrachero JM, Cuatrecases G, García EL, López-Fernández J, Lozano-García S, Bayón ÁM, Niño-Azcarate CM, Laclaustra O, Fuentealba P.   +14 more
europepmc   +1 more source

Real-world experience with insulin glargine U300 in pediatric type 1 diabetes: glycemic control, insulin requirements, and patient-reported outcomes. [PDF]

BMC Endocr Disord
Altun I, Güneş Kaya D, Uçar M, Gözderesi Y, Haşlak GV, Karakaş H, Bayramoğlu E, Evliyaoglu O, Turan H.   +8 more
europepmc   +1 more source

Economic evaluation of insulin glargine compared with human insulin for youth with type 1 diabetes in Tanzania and Bangladesh. [PDF]

PLoS One
Prust ML, Lalama CM, Kehlenbrink S, Akinola OA, Nyarubamba R, Flabe AH, Foulds A, Ogle GD, Majaliwa E, Zabeen B, Ramaiya K, Garvin A, Luo J.   +12 more
europepmc   +1 more source

Insulin glargine 300 U/mL safety data in pregnancy. [PDF]

Diabetes Obes Metab
Westerbacka J, Duverne M, Grulovic N, Thummisetti S, Doder Z.   +4 more
europepmc   +1 more source

Update on insulin glargine use in diabetic cats

, 2005
Glargine is a new human synthetic insulin analogue produced by recombinant DNA technology utilizing E.Coli. It differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the B-chain ...
Rand, Jacquie, Marshall, Rhett
core  

Importance of targeting post-prandial hyperglycaemia to achieve HbA1c goals in insulin glargine-treated subphenotypes of type 2 diabetes. [PDF]

Diabetes Obes Metab
Landgraf W, Owens DR, Frier BM, Bolli GB.   +3 more
europepmc   +1 more source